Literature DB >> 14531968

The need for pediatric studies of allergy and asthma medications.

Stanley J Szefler1, Glenn Whelan, Melanie Gleason, Joseph D Spahn.   

Abstract

For many years, clinicians have accepted the fact that most medications do not have dosing guidelines for children younger than 12 years of age. Recently, there has been a great effort to correct this deficiency. With the introduction of the 1997 Food and Drug Administration Modernization Act, a provision was established to grant additional market exclusivity to pharmaceutical firms that performed the required studies that would lead to improved labeling of medications for children. This effort has resulted in a significant advance for the management of asthma and allergic disorders in children. Several allergy and asthma medications are now approved for use in children as young as 1 year of age, with studies currently being conducted in younger age groups. In this review, we discuss the background for this effort and the continuing impact it will have on the future management of allergy and asthma in children.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14531968     DOI: 10.1007/s11882-003-0058-x

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.919


  28 in total

Review 1.  The Melbourne Asthma Study: 1964-1999.

Authors:  Peter D Phelan; Colin F Robertson; Anthony Olinsky
Journal:  J Allergy Clin Immunol       Date:  2002-02       Impact factor: 10.793

Review 2.  Advances in allergic skin diseases.

Authors:  Donald Y M Leung; Mark Boguniewicz
Journal:  J Allergy Clin Immunol       Date:  2003-03       Impact factor: 10.793

Review 3.  Advances in childhood asthma: hygiene hypothesis, natural history, and management.

Authors:  Andrew H Liu; Stanley J Szefler
Journal:  J Allergy Clin Immunol       Date:  2003-03       Impact factor: 10.793

4.  Long-term effects of budesonide or nedocromil in children with asthma.

Authors:  Stanley Szefler; Scott Weiss; James Tonascia; N Franklin Adkinson; Bruce Bender; Reuben Cherniack; Michele Donithan; H William Kelly; Joseph Reisman; Gail G Shapiro; Alice L Sternberg; Robert Strunk; Virginia Taggart; Mark Van Natta; Robert Wise; Margaret Wu; Robert Zeiger
Journal:  N Engl J Med       Date:  2000-10-12       Impact factor: 91.245

5.  A clinical index to define risk of asthma in young children with recurrent wheezing.

Authors:  J A Castro-Rodríguez; C J Holberg; A L Wright; F D Martinez
Journal:  Am J Respir Crit Care Med       Date:  2000-10       Impact factor: 21.405

6.  A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis.

Authors:  Hans Bisgaard
Journal:  Am J Respir Crit Care Med       Date:  2002-10-03       Impact factor: 21.405

7.  Difficult-to-control asthma: clinical characteristics of steroid-insensitive asthma.

Authors:  M T Chan; D Y Leung; S J Szefler; J D Spahn
Journal:  J Allergy Clin Immunol       Date:  1998-05       Impact factor: 10.793

Review 8.  Children with difficult asthma: a practical approach.

Authors:  D N Payne; I M Balfour-Lynn
Journal:  J Asthma       Date:  2001-05       Impact factor: 2.515

9.  The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.

Authors:  M Solèr; J Matz; R Townley; R Buhl; J O'Brien; H Fox; J Thirlwell; N Gupta; G Della Cioppa
Journal:  Eur Respir J       Date:  2001-08       Impact factor: 16.671

10.  Asthma and wheezing in the first six years of life. The Group Health Medical Associates.

Authors:  F D Martinez; A L Wright; L M Taussig; C J Holberg; M Halonen; W J Morgan
Journal:  N Engl J Med       Date:  1995-01-19       Impact factor: 91.245

View more
  1 in total

Review 1.  An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences.

Authors:  Aaron S Kesselheim
Journal:  Milbank Q       Date:  2011-09       Impact factor: 4.911

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.